Payment overview · 2025
General Payments
$1,759.85
92 reported records · 22 companies
Healthcare provider profile · identity verified
Shirley Mcmillin, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · AZLE, TX · NPI 1457720013
Verified facts
What the public records show
CMS Open Payments records show Shirley Mcmillin, NP received $1,759.85 in general payments during 2025 across 92 reported records.
ABBVIE INC. accounted for 18.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Nurtec Odt, Ozempic, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $321.89 | 18.3% | 18 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $228.55 | 13.0% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $207.03 | 11.8% | 16 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $204.05 | 11.6% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $164.23 | 9.3% | 9 | 2025 |
| Avvisto Therapeutics, LLC | Unresolved — no canonical attribution shown | $104.26 | 5.9% | 6 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $99.00 | 5.6% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $57.11 | 3.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $50.10 | 2.9% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $46.84 | 2.7% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $43.63 | 2.5% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $38.78 | 2.2% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $29.05 | 1.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $28.94 | 1.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $26.35 | 1.5% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $23.71 | 1.4% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.76 | 1.1% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $17.48 | 1.0% | 1 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $15.42 | 0.9% | 1 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $14.35 | 0.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.23 | 0.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $6.09 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,660.85 | 91 |
| Education | $99.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $321.89 | 18 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $228.55 | 8 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $204.05 | 11 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $171.43 | 9 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $164.23 | 9 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $145.78 | 8 | 2025 |
Source payment records
|
|||||
| CYCLOSET Normalized: cycloset |
Drug | Avvisto Therapeutics, LLC | $104.26 | 6 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $57.11 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $50.10 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $46.84 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $43.63 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $38.78 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $35.60 | 7 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $29.05 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $28.94 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $28.94 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $26.35 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $23.71 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $23.71 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $18.76 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $15.42 | 1 | 2025 |
Source payment records
|
|||||
| Secuado Normalized: secuado |
Drug | Noven Therapeutics, LLC | $14.35 | 1 | 2025 |
Source payment records
|
|||||
| Xelstrym Normalized: xelstrym |
Drug | Noven Therapeutics, LLC | $14.35 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.23 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $6.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 81 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 66 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 66 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 48 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
66 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
48 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
66 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
66 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
58 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
81 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 401 | 118 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 344 | 112 |
| Lisinopril | Lisinopril | 342 | 120 |
| Gabapentin | Gabapentin | 339 | 107 |
| Atorvastatin Calcium | Atorvastatin Calcium | 324 | 108 |
| Amlodipine Besylate | Amlodipine Besylate | 280 | 79 |
| Metformin Hcl | Metformin Hcl | 210 | 71 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 195 | 67 |
| Furosemide | Furosemide | 166 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 162 | 54 |
| Omeprazole | Omeprazole | 160 | 52 |
| Buspirone Hcl | Buspirone Hcl | 159 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 153 | 48 |
| Montelukast Sodium | Montelukast Sodium | 148 | 49 |
| Alprazolam | Alprazolam | 136 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 130 | 42 |
| Simvastatin | Simvastatin | 124 | 43 |
| Losartan Potassium | Losartan Potassium | 123 | 38 |
| Tramadol Hcl | Tramadol Hcl | 121 | 28 |
| Meloxicam | Meloxicam | 117 | 39 |
| Carvedilol | Carvedilol | 111 | 35 |
| Trazodone Hcl | Trazodone Hcl | 110 | 35 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 109 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 108 | 40 |
| Sertraline Hcl | Sertraline Hcl | 108 | 34 |
| Potassium Chloride | Potassium Chloride | 100 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 95 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 88 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 87 | 25 |
| Eliquis | Apixaban | 81 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 77 | 18 |
| Clonazepam | Clonazepam | 74 | 14 |
| Bupropion Xl | Bupropion Hcl | 72 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | 18 |
| Jardiance | Empagliflozin | 66 | 25 |
| Ozempic | Semaglutide | 66 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 64 | 22 |
| Methocarbamol | Methocarbamol | 63 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 62 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 20 |
| Rybelsus | Semaglutide | 58 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 22 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 55 | 17 |
| Ondansetron Odt | Ondansetron | 55 | 13 |
| Alendronate Sodium | Alendronate Sodium | 54 | 17 |
| Celecoxib | Celecoxib | 54 | 14 |
| Allopurinol | Allopurinol | 53 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 50 | 17 |
| Lorazepam | Lorazepam | 50 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 49 | 18 |
| Metformin Hcl Er | Metformin Hcl | 49 | 16 |
| Atenolol | Atenolol | 48 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | 17 |
| Prednisone | Prednisone | 47 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | 14 |
| Glipizide | Glipizide | 46 | 16 |
| Mounjaro | Tirzepatide | 43 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | 11 |
| Glimepiride | Glimepiride | 40 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 38 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 37 | 12 |
| Ezetimibe | Ezetimibe | 36 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 14 |
| Pregabalin | Pregabalin | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 33 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | 12 |
| Clonidine Hcl | Clonidine Hcl | 31 | 13 |
| Donepezil Hcl | Donepezil Hcl | 31 | 11 |
| Trulicity | Dulaglutide | 31 | suppressed |
| Cefdinir | Cefdinir | 30 | 22 |
| Famotidine | Famotidine | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | 12 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 28 | suppressed |
| Eszopiclone | Eszopiclone | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 23 |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 14 |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Vraylar | Cariprazine Hcl | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 15 |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 13 |
| Nurtec Odt | Rimegepant Sulfate | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Larin Fe | Norethindrone-E.Estradiol-Iron | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Buprenorphine | Buprenorphine | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,759.85 · 92 records | ABBVIE INC. | AREXVY, Auvelity, CAPLYTA, CYCLOSET, Dexcom G6 Transmitter, Doc Band, ELIQUIS, FREESTYLE LIBRE, Heplisav-B, INSPIRE, JARDIANCE, Korlym, MOUNJARO, NURTEC ODT, Natroba, Ozempic, SHINGRIX, Secuado, Spinosad, TRELEGY ELLIPTA, TZIELD, VOQUEZNA, VRAYLAR, XYOSTED, Xelstrym, YUPELRI, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error